Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on developing innovative engineered T cell therapies to treat autoimmune diseases. Their proprietary Cabaletta Approach to B cell Ablation (CABA®) platform utilizes two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T (CAART) cells. The CARTA approach aims to transiently eliminate all B cells through a single infusion, potentially resetting the immune system. Meanwhile, CAART candidates target only disease-causing B cells, aiming to eradicate the cause of disease without affecting the humoral immune system.

Cabaletta Bio is actively advancing their lead CARTA candidate, CABA-201, in clinical trials for systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis. They also have clinical-stage CAART candidates for mucosal pemphigus vulgaris and MuSK myasthenia gravis. The company believes their CABA® platform has the potential to deliver durable, potentially curative responses, eliminating the need for chronic immune suppressive therapies and offering hope for patients suffering from various autoimmune diseases.

Cabaletta Bio offers a number of remote job opportunities across various departments. The company's job listings specify whether a role is remote or in-office, including specific locations. While they do not offer details about flexibility beyond location, their commitment to employee wellbeing suggests potential for flexible work arrangements, especially for remote employees.

Cabaletta Bio is a clinical-stage biotechnology company focused on developing engineered T cell therapies to treat autoimmune diseases. Their mission is to harness the power of the immune system through innovative cell and gene therapies to deliver accessible cures for patients suffering from these debilitating conditions. They are working to develop and launch the first targeted cellular therapies for patients with autoimmune diseases, aiming to provide deep, durable, and potentially curative responses by eliminating the need for chronic immune suppression.

Cabaletta Bio values a team-first culture focused on developing novel cell therapies to transform the treatment of autoimmune diseases. They prioritize the patient, listen to data, and encourage continuous improvement and excellence, while embracing differences and demanding equity to create a culture of trust.

Cabaletta Bio is committed to fostering a diverse, equitable, and inclusive workplace. Their “get REAL” initiative promotes reflection, education, and action within the company, encouraging open communication and dialogue about diversity, equity, and inclusion. This initiative aims to build a culture where employees feel valued, respected, and empowered to contribute their unique perspectives and talents. Cabaletta actively embraces differences and is committed to creating a fair and trusting environment for all employees.